Neurocrine Bioscienc (NBIX)

$NBIX Neurocrine Biosciences stock, watch for an upside gap breakout at https://stockconsultant.com/?NBIX

Neurocrine's new Phase 4 data shows INGREZZA significantly improves quality of life in older adults with TD. Presented at AANP today, this builds on their robust clinical evidence. $NBIX continues to strengthen its position in movement disorders. Bullish as real-world impact meets aging population needs. https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-data-showing-significant-patient-reported-improvements-in-health-related-quality-of-life-with-ingrezza-valbenazine-capsules-in-older-adults-with-tardive-dyskinesia-302485804.html

$NBIX Neurocrine presents new data on patient-reported improvements with INGREZZA Neurocrine Biosciences announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA capsules. Findings will be presented at the 2025 American Association of Nurse Practitioners National Conference in San Diego. These post-hoc analyses of older adults expand on recently announced Phase 4 study results, which demonstrated that continued treatment with INGREZZA improved functional status and quality of life measures across the general patient population. Patients who received continued treatment with INGREZZA reported significant improvements in health-related quality of life and functional status, compared with those randomized to placebo. Two clinically validated scales were used to assess patient-reported outcomes, providing a comprehensive and scientifically robust measure of health status: The EuroQol 5-Dimension 5-Level assessment tool, which measures health-related quality of life across five dimensions of health status; The Sheehan Disability Scale, which measures patient-reported functional impairment in work/school, social life and family/home life impairment.

RBC Capital⬆️ $XENE PT to $57 from $55, reit'd its OP and said, "Analysis Shows Strong Historical Ph.Il to Ph.III Translatability For Epilepsy Drugs" $BHVN $NBIX $JAZZ RBC added, "Our analysis of historical focal onset efficacy studies shows high translatability between ph.Il and ph.Ill on seizure reductions and responder rate, suggesting a good likelihood azetukalner's ph.Ill data early next year should mostly recapitulate their promising ph.Il data. Even under conservative assumptions, azetukalner's efficacy, novel Kv7 MOA, rapid onset, and potential mood benefits, in a space dominated by polypharmacy, should be highly competitive and give the drug an impt, $1.2B (RBCe) future role. Therapeutic window remains key, though having two tested dose options should help real-world pt management. Shares appear to underappreciate azetukalner's opportunity; increasing tgt to $57 on higher PoS and see favorable stock setup into ph.Ill data."

$NBIX Buy &Hold. For more information visit my site. Investment Scoreboard:

$NBIX = BEAUTIFUL 😍 3 month chart! WOW 📈📈

5 Biotech Stocks with great growth Potential 🧬 • $VRTX – Gene therapy approvals gaining traction • $CRSP – Advancing CRISPR pipeline toward late stage • $NBIX – Neurology assets showing strong trial results • $REGN – Diversified biologics revenue + AI in drug discovery • $AKRO – NASH pipeline could be a long-term win Follow us for more daily alerts 🔱

RBC Capital updates rating for Neurocrine Biosciences ( $NBIX ) to Outperform, target set at 145.

$NBIX From share buybacks to Phase 3 trials, Neurocrine Biosciences is executing on all fronts. See why analysts are bullish on NBIX stock. https://biotechhealthx.com/biotech-news/neurocrine/

$NBIX the 3 month NBIX chart is showing a very Bullish phase has begun 📈

$NBIX my guess would be NVS

$NBIX set up for a buy out.

$NBIX buying below 100 really was a no brainer here

$NBIX Neurocrine's Crenessity shows further efficacy in Phase 3 CAH study Neurocrine announced new data from the Phase 3 CAHtalyst Adult and Pediatric studies of Crenessity - crinecerfont -. The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia, or CAH, achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. Results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando. CAH is characterized by imbalances in hormone production, including cortisol, aldosterone and androgens, which cause a wide range of symptoms and can lead to long-term health problems. 90% of participants on CRENESSITY versus 21% on placebo achieved greater than or equal to1 threshold for A4 reduction or GC reduction. In contrast, no patients who were treated with placebo achieved a physiologic GC dose, and nearly 70% still had elevated A4 levels. Select reproductive hormone changes in adult males with classic CAH who received up to one year of Crenessity were evaluated from the CAHtalyst Adult study. A higher percentage of male patients who had abnormal levels had observed rates of normalization of LH and A4/T with Crenessity vs. placebo, respectively, despite greater decreases in GC dose in the CRENESSITY group.

$NBIX delivers knockout data: 90% of pediatric CAH patients hit key endpoints with CRENESSITY vs 21% on placebo. Adult males show hormone normalization even with reduced steroids. Fresh Phase 3 results today reinforce this $2B+ market play. FDA-approved since 2024 - execution looks solid. https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-data-on-improvements-in-physiologic-glucocorticoid-dosing-and-select-reproductive-hormones-in-patients-with-classic-congenital-adrenal-hyperplasia-taking-crenessity-crinecerfont-302457026.html

$NBIX Neurocrine presents further evidence of the impact of higher glucocorticoid dose Neurocrine presented a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting in Montreal. Congenital adrenal hyperplasia, or CAH, is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids or GCs, which increase the risk of complications across multiple aspects of health. This systematic literature review is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH. More than half of the publications found statistically significant associations between GC dose and clinical outcomes.

BofA in a Broad Research Note Provided its Takeaways from Day 1 of their Health Care Conf. for: $ACAD $APLS ARVN BNTX DNLI INCY $NBIX $OCUL PTCT $RARE RNA Re: $OCUL BofA said, "Axpaxli superiority study readout on track for 1Q26 — We reiterate our Buy with $17 PO:" BofA added:

$NBIX monster mothly base. Looking coiled on the daily

Chardan🏁 $XENE Buy-$55, said " $XENE: Validating the Kv7 Approach; Initiate with Buy; $55 PT" $BHVN $NBIX $JAZZ Chardan said in its initiation report:

$NBIX CYDY

Piper Sandler updates rating for Neurocrine Biosciences ( $NBIX ) to Overweight, target set at 160 → 154.

$NBIX post-earnings wrap-up: 🧪 +13.3% today after Q1 revenue 🧪 SIX price target hikes followed 🧪 options bulls (7x norm calls today) 🧪 most popular option: May 130-strike calls 🧪stock is still -12.9% YOY 🧪 on track for 3rd straight green day and best day since Nov '20!!